GlycoMark (1,5-AG) Rate-of-Change Interpretation

What GlycoMark (1,5-AG) Actually Measures

GlycoMark measures serum 1,5-anhydroglucitol (1,5-AG), a dietary monosaccharide that is reabsorbed in the renal tubule in direct competition with glucose. When plasma glucose exceeds approximately 180 mg/dL, the glucose load saturates tubular reabsorption and competitively displaces 1,5-AG into urine, causing serum levels to fall. The result is a marker that selectively captures postprandial spikes rather than sustained average glucose. ADA 2024 Standards of Care, Section 6

The Renal Threshold Mechanism

The 180 mg/dL threshold is not arbitrary. It corresponds to the renal glucose threshold at which tubular glucose transport becomes saturated. Below that level, essentially no competitive displacement of 1,5-AG occurs and serum concentrations remain stable. Above it, every additional glucose spike accelerates urinary 1,5-AG loss. This mechanism means the test is exquisitely sensitive to excursions but blind to glucose fluctuations that stay under the threshold.

Half-Life and Time Window

The serum half-life of 1,5-AG after a change in glycemic control is approximately 3 to 5 days, and steady-state equilibrium after a sustained change is reached in roughly 7 to 14 days. Dungan KM, 2008, Clin Chem This is meaningfully faster than HbA1c, which reflects a 90-day average. A clinician ordering repeat GlycoMark after a dietary or pharmacologic change can see a real signal within two weeks rather than three months.

Why the Direction Is Inverted

Unlike HbA1c, where higher values signal worse control, 1,5-AG is consumed by poor glucose control. A value of 5 mcg/mL is far worse than 25 mcg/mL. This inverse relationship trips up both patients and clinicians who are accustomed to "higher is better" biomarkers. The mnemonic worth remembering: 1,5-AG falls when glucose rises.

GlycoMark Normal Range and Optimal Targets

The laboratory reference range and the clinically optimal target are not the same number. Reference ranges are population-derived cutoffs; optimal targets reflect what predicts the lowest long-term cardiometabolic risk.

Standard Laboratory Reference Range

Quest Diagnostics and the original validation studies cite a reference interval of approximately 10.7 to 32.0 mcg/mL for non-pregnant adults without diabetes. Stettler C et al., 2006, Diabetologia Values below 10.7 mcg/mL are classified as consistent with poorly controlled or uncontrolled postprandial hyperglycemia. Values above 32.0 mcg/mL are uncommon and not clinically concerning in isolation.

Population-Specific Ranges

Sex and ethnicity affect baseline 1,5-AG. Women have slightly lower mean values than men. Asian populations, particularly Japanese individuals, show higher baseline serum concentrations, likely reflecting higher dietary intake of 1,5-AG from foods such as wheat and soybeans. Yamanouchi T et al., 1989, Diabetes Clinicians should account for ethnicity when interpreting borderline values.

The ranges by glycemic status, as described in the ADA literature, approximate the following:

| Glycemic Status | Approximate 1,5-AG (mcg/mL) | |---|---| | Non-diabetic, well-controlled | 14 to 32 | | Controlled type 2 diabetes | 6 to 14 | | Poorly controlled type 2 diabetes | <6 | | Markedly uncontrolled | <2 |

The Longevity Medicine Optimal Target

Longevity-focused clinicians frequently set a higher bar than the conventional "above 10.7" cutoff. In observational data, 1,5-AG values above 21 mcg/mL in non-diabetic adults correlate with CGM-derived time-in-range above 90 percent and minimal postprandial area-under-curve exceedance. Selvin E et al., 2011, Diabetes Care The practical clinical target for a metabolically healthy adult seeking to minimize glucose variability is therefore greater than 21 mcg/mL, not merely above the lower reference limit.

The HealthRX clinical team uses a three-tier framework for non-diabetic patients:

• Optimal (low glycemic burden): greater than 21 mcg/mL
• Borderline (subclinical postprandial excursions likely): 14 to 21 mcg/mL
• Actionable (significant excursions, intervention warranted): below 14 mcg/mL

This framework does not replace CGM data; it complements it when CGM is not in use.

Rate-of-Change Interpretation: What Trends Tell You That a Single Value Cannot

A single GlycoMark result tells you the approximate current postprandial glucose burden. Serial results tell you whether an intervention is working, a diet has changed, or a medication is suppressing the marker for non-glycemic reasons.

Calculating a Meaningful Rate of Change

Because steady state takes 7 to 14 days, the minimum interval for a meaningful repeat test is two weeks. Testing more frequently creates noise, not signal. The rate-of-change formula used clinically is straightforward:

Delta 1,5-AG = (Value at T2) minus (Value at T1)

A delta of plus 3 mcg/mL or more over a 4-week interval is a clinically meaningful improvement, based on the intra-individual coefficient of variation for the assay of roughly 5 to 8 percent at concentrations near 10 mcg/mL. Dungan KM et al., 2006, Diabetes Care A delta of minus 3 mcg/mL or more is a meaningful worsening signal warranting investigation.

Rising 1,5-AG: What It Signals

A rising value over 2 to 8 weeks indicates that glucose is spending less time above 180 mg/dL. This may follow:

• Introduction of a GLP-1 receptor agonist (semaglutide, tirzepatide) blunting postprandial peaks
• Dietary carbohydrate restriction reducing postprandial load
• Addition of a short-acting or rapid-acting insulin analog covering meals
• Resolution of an acute illness that was transiently worsening glycemia

In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points vs. 1.86 for semaglutide 1 mg at 40 weeks. Frías JP et al., 2021, NEJM GlycoMark would be expected to rise in parallel with that HbA1c improvement, particularly because tirzepatide has a pronounced effect on postprandial glucose through its dual GIP/GLP-1 mechanism.

Falling 1,5-AG: What It Signals

A falling value despite stable or improving HbA1c is one of the most clinically actionable patterns in glucose monitoring. It indicates postprandial spikes are worsening while the overnight and fasting glucose components of HbA1c remain controlled. This divergence is common in:

• Patients with type 1 diabetes increasing carbohydrate intake without matching insulin adjustment
• Type 2 patients whose mealtime glucose is rising as beta-cell function declines
• Non-diabetic adults with early insulin resistance who spike well above 180 mg/dL after high-glycemic meals despite normal fasting glucose and HbA1c

The ADAG study (N=507) confirmed that HbA1c-to-average-glucose correlation is weakest in patients with the highest glucose variability. Nathan DM et al., 2008, Diabetes Care A falling 1,5-AG in that context is the early warning sign that HbA1c is not capturing.

Stable 1,5-AG: Reassurance or False Reassurance?

A stable value is reassuring only if it is stable at an optimal level. A value that holds at 7 mcg/mL across three monthly measurements confirms persistently poor postprandial control, not stability to celebrate. A value stable at 24 mcg/mL across the same interval provides genuine reassurance. Always interpret stability relative to where the value sits on the range, not merely whether it moved.

GlycoMark vs. HbA1c: When Each Test Wins

These two markers answer different questions. HbA1c reflects mean glucose over 90 days, weighted toward the most recent weeks. GlycoMark reflects whether glucose has crossed the 180 mg/dL postprandial threshold over the past 1 to 2 weeks.

When GlycoMark Outperforms HbA1c

GlycoMark adds information that HbA1c cannot provide in several specific clinical situations:

Hemoglobinopathies and hemolytic conditions. HbA1c is unreliable in sickle cell trait, thalassemia, and any condition that shortens red-cell lifespan. GlycoMark is unaffected by red-cell turnover. The ADA Standards of Care (2024) explicitly recommend alternative glycemic markers in these populations. ADA 2024, Section 2

Early postprandial dysglycemia detection. Selvin et al. (2011) demonstrated in a community-based cohort that 1,5-AG predicted incident diabetes and cardiovascular events independently of HbA1c, particularly in individuals in the high-normal HbA1c range (5.5 to 5.9%). Selvin E et al., 2011, Diabetes Care

Short-term medication response. A GLP-1 agonist started two weeks ago is already visible in a GlycoMark result. The corresponding HbA1c shift will not be meaningful for another 6 to 8 weeks.

When HbA1c Outperforms GlycoMark

HbA1c remains the reference standard for diagnosing diabetes, tracking long-term control, and predicting microvascular complication risk. The DCCT trial (N=1,441) established that intensive control with HbA1c below 7% reduced retinopathy progression by 76% and nephropathy by 54%. DCCT Research Group, 1993, NEJM No comparable long-term outcome data exist for GlycoMark targets.

Critical Confounders That Invalidate the GlycoMark Result

Several conditions suppress serum 1,5-AG through mechanisms unrelated to postprandial glucose control. Failing to account for these produces a falsely low result that looks like poor glycemic control when it is not.

SGLT2 Inhibitors

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) block renal glucose reabsorption at the SGLT2 transporter. This same transporter handles 1,5-AG reabsorption. A patient on an SGLT2 inhibitor will have a chronically suppressed 1,5-AG regardless of actual postprandial glucose levels. GlycoMark is not interpretable in this population. Bonora BM et al., 2015, Diabetes Care

Pregnancy

Renal glucose threshold decreases during pregnancy due to increased GFR, causing 1,5-AG loss even at normal glucose concentrations. Values below 10 mcg/mL are common in healthy pregnant women and do not indicate glycemic dysfunction. Always check pregnancy status before ordering or interpreting this test.

Severe Renal Impairment

Reduced GFR decreases 1,5-AG urinary clearance, causing values to rise artifactually. In patients with eGFR below 30 mL/min/1.73 m², 1,5-AG concentrations may be elevated despite poor glucose control, producing false reassurance.

Dietary Restriction of 1,5-AG Sources

Very low-carbohydrate and ketogenic diets that eliminate wheat, rice, and legumes may reduce dietary intake of 1,5-AG substantially. This can suppress baseline serum concentrations independent of glucose control. The clinical implication: a patient on a strict ketogenic diet who shows a borderline-low 1,5-AG may not have the postprandial excursions the number implies.

Integrating GlycoMark Into a Serial Monitoring Protocol

Serial GlycoMark monitoring is most productive when embedded in a structured protocol rather than ordered ad hoc. The following approach reflects current evidence and the HealthRX clinical team's recommendations.

Baseline and Follow-Up Cadence

Order the baseline GlycoMark together with fasting glucose, HbA1c, fasting insulin, and a full metabolic panel. This establishes the patient's glycemic picture across multiple time windows simultaneously.

For patients starting a new glucose-lowering intervention (dietary, pharmacologic, or both), repeat GlycoMark at 4 weeks and again at 12 weeks. The 4-week value tells you whether the intervention is producing early postprandial benefit; the 12-week value, combined with a repeat HbA1c, provides a complete picture. Dungan KM et al., 2006, Diabetes Care

For metabolically stable patients undergoing annual wellness labs, a single annual GlycoMark alongside HbA1c is sufficient.

Pairing GlycoMark with CGM Data

When a patient wears a continuous glucose monitor (CGM), GlycoMark and CGM time-in-range (TIR) should converge. A TIR above 70% (the consensus target from the Advanced Technologies and Treatments for Diabetes, ATTD, 2019 consensus) Battelino T et al., 2019, Diabetes Care corresponds roughly to a 1,5-AG above 14 mcg/mL. Significant divergence between GlycoMark and TIR should prompt a review of CGM calibration, dietary logging, and the confounders listed above.

Interpreting Change in Context of Baseline

The clinical weight of a rate-of-change signal depends on where the patient started. A rise from 4 to 7 mcg/mL is a 75% relative improvement and clinically meaningful, but the patient remains in the poorly controlled range and requires ongoing intervention. A rise from 19 to 22 mcg/mL confirms optimization and supports de-escalation of monitoring frequency.

Dr. Elizabeth Selvin, whose work remains the most-cited on 1,5-AG in population cohorts, noted that "1,5-anhydroglucitol may be a useful short-term marker of glycemic control and could complement HbA1c in clinical decision-making." Selvin E et al., 2011, Diabetes Care

Special Populations: Adjusted Targets and Interpretation Caveats

Type 1 Diabetes

In type 1 diabetes, 1,5-AG is a particularly useful adjunct because glycemic variability is high and postprandial coverage is entirely dependent on exogenous insulin dosing. The Diabetes Control and Complications Trial (DCCT) and subsequent EDIC follow-up established that reducing postprandial excursions reduces microvascular risk. DCCT/EDIC Research Group, 2005, NEJM In this population, a target 1,5-AG above 14 mcg/mL (consistent with controlled diabetes) is a reasonable minimum; above 21 mcg/mL is achievable with tight closed-loop insulin delivery.

Older Adults

The NHANES 2003-2006 data demonstrated that 1,5-AG declines with age even in non-diabetic populations, possibly reflecting subtle age-related increases in postprandial glucose exceedance. Selvin E et al., 2011, Diabetes Care Clinicians should apply age-adjusted benchmarks and avoid over-treating borderline-low values in adults over 75 in the absence of other glycemic abnormalities.

Women on Hormone Therapy

Estrogen affects insulin sensitivity and postprandial glucose handling. Women initiating menopause hormone therapy (MHT) may see modest improvements in postprandial glucose, reflected in rising 1,5-AG over 8 to 12 weeks. A study in the Journal of Clinical Endocrinology and Metabolism found that oral estradiol worsened insulin resistance while transdermal estradiol preserved it, a difference that could plausibly appear in serial 1,5-AG values. Salpeter SR et al., 2006, JCEM Ordering a baseline GlycoMark before starting MHT and repeating at 12 weeks provides an early metabolic check.

Practical Decision Points for HealthRX Clinicians

A few direct decision rules follow from the evidence above.

Order GlycoMark when HbA1c may be unreliable (hemoglobinopathy, recent transfusion, end-stage renal disease with elevated hematocrit), when postprandial dysglycemia is suspected in a patient with normal fasting glucose and HbA1c below 5.7%, or when evaluating short-term response to a dietary or medication change within the past two to six weeks.

Do not order GlycoMark in patients currently taking SGLT2 inhibitors, in pregnant women, or in patients with eGFR below 30 mL/min/1.73 m² without explicitly noting the confounder in the interpretation.

A falling 1,5-AG over 4 to 8 weeks in the absence of SGLT2 inhibitor use or pregnancy warrants a dietary review, fasting insulin, and consideration of CGM placement. It does not require an HbA1c recalculation; the 1,5-AG is telling you what HbA1c will miss for another 6 to 10 weeks.

The Endocrine Society's 2022 Clinical Practice Guideline on diabetes technology states that "short-term glycemic markers including 1,5-AG may provide incremental clinical information particularly for identifying postprandial hyperglycemia in patients with near-normal HbA1c." Endocrine Society, 2022, JCEM